Literature DB >> 11772149

Pharmacogenetic tactics and strategies: implications for paediatrics.

W W Weber1.   

Abstract

Genetic diversity exerts profound effects on variation in human drug response in adults, but comparatively little research that specifically relates to genetically abnormal responses in infancy and childhood has been reported. Specific genetic changes in human enzymes, receptors and other proteins that are implicated in drug response and their associated phenotypic correlates provide needed data for construction of profiles individualised to predict susceptibility to adverse drug reactions. If therapy adheres to such guidelines, failure to respond to drug therapy and drug toxicity among genetically susceptible persons can be greatly minimised or averted.

Entities:  

Mesh:

Year:  2001        PMID: 11772149     DOI: 10.2165/00128072-200103120-00001

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  102 in total

1.  Intolerance to lactose and other dietary sugars.

Authors:  D M Swallow; M Poulter; E J Hollox
Journal:  Drug Metab Dispos       Date:  2001-04       Impact factor: 3.922

Review 2.  Gene-expression analysis at the single-cell level.

Authors:  A K Dixon; P J Richardson; R D Pinnock; K Lee
Journal:  Trends Pharmacol Sci       Date:  2000-02       Impact factor: 14.819

3.  Mutation detection and single-molecule counting using isothermal rolling-circle amplification.

Authors:  P M Lizardi; X Huang; Z Zhu; P Bray-Ward; D C Thomas; D C Ward
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

4.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.

Authors:  J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

Review 5.  Pharmacogenetics in pediatrics. Implications for practice.

Authors:  J S Leeder; G L Kearns
Journal:  Pediatr Clin North Am       Date:  1997-02       Impact factor: 3.278

6.  Alcohol dehydrogenase-2*3 allele protects against alcohol-related birth defects among African Americans.

Authors:  D G McCarver; H R Thomasson; S S Martier; R J Sokol; T Li
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

Review 7.  Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract.

Authors:  R H Tukey; C P Strassburg
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

8.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Authors:  S Billecke; D Draganov; R Counsell; P Stetson; C Watson; C Hsu; B N La Du
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

9.  Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype.

Authors:  J Turki; J Pak; S A Green; R J Martin; S B Liggett
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

View more
  1 in total

1.  Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children.

Authors:  Björn Andersson; Gunnel Hellgren; Andreas F M Nierop; Ze'ev Hochberg; Kerstin Albertsson-Wikland
Journal:  Proteome Sci       Date:  2009-11-02       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.